Generex Biotechnology Corp. (fka GNBTQ)

[suny66]

Recent Facts
1. EpiVax will be using the the Covid-19 vaccine and will be developed using Generex’s li-Key immune system activation technology. Credit: Bruno /Germany from Pixabay.
2. EpiVax worked for 21 years to be able to make a vaccine in 24 hours! (From EpiVax web site. https://www.pharmaceutical-technology.com/news/generex-covid-19-vaccine/
3. EpiVaxa private biopharm company is working in collaborarion with Generex.
4. GNBT has signed a contract with EpiVax. https://epivax.com/news/press-release-generex-signs-contract-with-epivax-to-develop-ii-key-peptide-vaccines-to-address-the-coronavirus-pandemic
4. EpiVax doing lab work both in Wuhan, China and Ross Labs at the University of Georgia.
5. EpiVax has solicited funds from NIH and has received funds from NIH in the past.
6. Generex will be doing human trials soon in China. IN ANIMAL TESTS. Will test on human subjects who had the Covid-19 virus in the past. If successful, FDA will be under pressure to approve the vaccine fast.
7. This all translates to GNBT being a huge winner way ahead of the other labs.
GNBT$$$$$